Aegis Therapeutics (Aegis) has signed a license agreement providing Roche access to it’s proprietary ProTek stabilisation technology. The ProTek technology covers the use of specific excipients as stabilizers in certain manufacturing processes and formulations of protein-based therapeutics.
Under the terms of the agreement, Aegis will receive undisclosed up-front licensing fees and individual product-related event and royalty payments.
Edward Maggio, chief executive officer of Aegis, said: “We are pleased to be working with Roche, an innovative world leader in monoclonal antibody and peptide based therapeutics. We view this agreement as a significant validation of our proprietary ProTek peptide and protein stabilisation technology.”
Aegis is a drug delivery technology company commercialising its patented drug delivery and drug formulation technologies through product-specific licenses.